Grant Sweep

Consolidated research funding across disease areas and research fields — federal, foundation, state & industry sources in one filterable place.

← Back to opportunities
OpenR61Clinical trial: Required

Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)

National Institutes of Health (NIH) · NIH Institute/Center · PAR-27-011

Source: Grants.gov · View original posting ↗

Award
Amount not listed
Deadline
Nov 2, 2028
Letter of intent
Mechanism
R61
Duration
Expected awards
Funding cycle
Standard NIH dates
Open date
Mar 18, 2026
Total funding
Clinical trial
Required
Small businessGovernmentHigher educationNonprofitForeign entities

Research areas

Basic mechanisms & biologyTherapeutics & drug discoveryClinical trialsPrevention & risk factors

Auto-classified from the title and description (keyword-based) — may be imperfect.

Description

This Notice of Funding Opportunity (NOFO) supports applications to develop and conduct investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or dissemination and implementation science clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, dissemination and implementation science clinical trials and/or prevention strategies. Trials for which this NOFO applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website.This NOFO will utilize a bi-phasic, milestone-driven mechanism of award. The objective of the application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, participant recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination. The application should also describe its approaches to increase community engagement from conceptual design of the intervention through implementation and sustainability, close gaps in health outcomes within the US population, and increase health for all.

Data notes: award amount not published in the source feed; administering NIH institute could not be identified from the opportunity number.